Previous studies have shown that the anti-tumor effect of CHK1 inhibitors is determined by p53 status, while other findings have illustrated that CHK1 inhibitors decrease cellular viability irrespective of p53 status [83,84,85]. This evidence concerns the gene TP53 and neoplasm.